Home

Why Choose Medcrave Mission & Vision Partners & Supporters News & Press Release

Journals eBooks Videos Reprints

Magazines Editors-in-Chief FAQs Contact Us ☰

Osimertinib in EGFR-Mutated NSCLC: benefits beyond disease-free survival and overall survival

: Journal of Lung, Pulmonary & Respiratory Research
: Ignacio Casarini,<sup>1</sup> Enrique Díaz Cantón<sup>2</sup>

PDF Full Text

Keywords

Osimertinib, EGFR,-Mutated NSCLC, disease-free survival, overall survival

© 2014-2025 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at www.medcrave.com
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera | Terms and Conditions | Privacy Policy

Testimonials